secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2026-06-10T20:09:58+00:00
Accession:  0001193125-26-265830
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene shareholders re-elect all four directors, ratify auditor at 2026 AGM
---------------------------------------------------------------------------

- 56,196,302 common shares voted (83.89% of outstanding) at June 9, 2026 AGM.
- All four director nominees elected with >99% votes cast in favor; broker non-votes ~8.8M.
- Auditor appointment and remuneration approved: 56,180,287 for, 16,015 against.
- No other significant proposals; no change in board composition or auditor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526265830/0001193125-26-265830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526265830/engn-20260609.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-265830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer